Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Novel functions of the luteinizing hormone/chorionic gonadotropin receptor in prostate cancer cells and patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Inflammation, non-endothelial dependent coronary microvascular function and diastolic function-Are they linked?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Dyslipidemia at diagnosis of childhood acute lymphoblastic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hashimoto's thyroiditis as a risk factor for thyroid cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Disease Control and Gender Predict the Socioeconomic Effects of Acromegaly: A Nationwide Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Ecological momentary assessments (EMAs) did not improve responsiveness of patient-reported outcomes on quality of life

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Is the alpha-galactosidase A variant p.Asp313Tyr (p.D313Y) pathogenic for Fabry disease? A systematic review

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

INTRODUCTION: Aromatase inhibitors (AIs) dramatically increased breast cancer (BC) survival, leading to enhanced attention to their long-term consequences on psychological functioning. Conflicting data has been examined regarding the association between AIs administration and the clinical psychological features in BC survivors (BCSs).

PURPOSE: As psychological symptoms often occur in such chronic diseases, our study aimed at exploring anxious and depressive symptoms and the perceived quality of life (QoL) in BCSs assessed for osteoporosis.

METHODS: The total sample consisted of a clinical sample of 51 outpatient postmenopausal women, diagnosed with BC, and a control group composed of 51 healthy postmenopausal women. All recruited participants were evaluated through the clinical gold standard interview and completed the following self-rating scales: the Hamilton Anxiety Rating Scale, Beck Depression Inventory II edition, and 36-Item Short Form Health Survey, which were administered at baseline and after 6 months in BCSs in AIs treatment, compared with controls. Moreover, all participants were assessed for vitamin D status, bone mineral density (BMD) and subclinical vertebral fractures. Data regarding age, age at menopause, body mass index (BMI), smoking habits and alcohol consumption was collected.

RESULTS: BCSs (n = 51) showed higher anxious and depressive symptoms, and lower perceived QoL vs. controls (n = 51) (p<0.05 for all). After 6 months of treatment with AIs, BCSs showed significant reduction of anxious and depressive symptoms and a significantly higher perceived QoL for both physical and mental components, vs. controls.

CONCLUSIONS: The improvement of clinical psychological features and perceived QoL was associated with AIs treatment in women being treated with, for early breast cancer. Further studies are needed to obtain a deeper comprehension of the correlation between clinical psychological and physical features in BCSs.

Original languageEnglish
JournalPLoS One
Volume15
Issue number3
Pages (from-to)e0230681
ISSN1932-6203
DOIs
Publication statusPublished - 26 Apr 2020

ID: 59977729